Postoperative Adjuvant Chemotherapy With Fluorouracil, Doxorubicin, Cyclophosphamide, and BCG Vaccine: A Follow-up Report

Aman U. Buzdar, George R. Blumenschein, Charles K. Tashima, Gabriel N. Hortobagyi, Jordan U. Gutterman, Evan M Hersh, Emil Freireich, Terry L. Smith, Edmund A. Gehan, Luis T. Campos, Warren L. Wheeler

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Two hundred twenty-two patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease. (JAMA 242:1509-1513, 1979).

Original languageEnglish (US)
Pages (from-to)1509-1513
Number of pages5
JournalJournal of the American Medical Association
Volume242
Issue number14
DOIs
StatePublished - Oct 5 1979
Externally publishedYes

Fingerprint

BCG Vaccine
Adjuvant Chemotherapy
Fluorouracil
Doxorubicin
Cyclophosphamide
Drug Therapy
Disease-Free Survival
Survival Rate
Heart Failure
Breast Neoplasms
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Postoperative Adjuvant Chemotherapy With Fluorouracil, Doxorubicin, Cyclophosphamide, and BCG Vaccine : A Follow-up Report. / Buzdar, Aman U.; Blumenschein, George R.; Tashima, Charles K.; Hortobagyi, Gabriel N.; Gutterman, Jordan U.; Hersh, Evan M; Freireich, Emil; Smith, Terry L.; Gehan, Edmund A.; Campos, Luis T.; Wheeler, Warren L.

In: Journal of the American Medical Association, Vol. 242, No. 14, 05.10.1979, p. 1509-1513.

Research output: Contribution to journalArticle

Buzdar, AU, Blumenschein, GR, Tashima, CK, Hortobagyi, GN, Gutterman, JU, Hersh, EM, Freireich, E, Smith, TL, Gehan, EA, Campos, LT & Wheeler, WL 1979, 'Postoperative Adjuvant Chemotherapy With Fluorouracil, Doxorubicin, Cyclophosphamide, and BCG Vaccine: A Follow-up Report', Journal of the American Medical Association, vol. 242, no. 14, pp. 1509-1513. https://doi.org/10.1001/jama.1979.03300140025017
Buzdar, Aman U. ; Blumenschein, George R. ; Tashima, Charles K. ; Hortobagyi, Gabriel N. ; Gutterman, Jordan U. ; Hersh, Evan M ; Freireich, Emil ; Smith, Terry L. ; Gehan, Edmund A. ; Campos, Luis T. ; Wheeler, Warren L. / Postoperative Adjuvant Chemotherapy With Fluorouracil, Doxorubicin, Cyclophosphamide, and BCG Vaccine : A Follow-up Report. In: Journal of the American Medical Association. 1979 ; Vol. 242, No. 14. pp. 1509-1513.
@article{19d1de5bfb11449e8a83ba336f59b7e4,
title = "Postoperative Adjuvant Chemotherapy With Fluorouracil, Doxorubicin, Cyclophosphamide, and BCG Vaccine: A Follow-up Report",
abstract = "Two hundred twenty-two patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83{\%} and 78{\%}, respectively, in the chemotherapy group and 64{\%} and 55{\%}, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93{\%} and 89{\%}, respectively, in the chemotherapy group and 84{\%} and 58{\%}, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease. (JAMA 242:1509-1513, 1979).",
author = "Buzdar, {Aman U.} and Blumenschein, {George R.} and Tashima, {Charles K.} and Hortobagyi, {Gabriel N.} and Gutterman, {Jordan U.} and Hersh, {Evan M} and Emil Freireich and Smith, {Terry L.} and Gehan, {Edmund A.} and Campos, {Luis T.} and Wheeler, {Warren L.}",
year = "1979",
month = "10",
day = "5",
doi = "10.1001/jama.1979.03300140025017",
language = "English (US)",
volume = "242",
pages = "1509--1513",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "14",

}

TY - JOUR

T1 - Postoperative Adjuvant Chemotherapy With Fluorouracil, Doxorubicin, Cyclophosphamide, and BCG Vaccine

T2 - A Follow-up Report

AU - Buzdar, Aman U.

AU - Blumenschein, George R.

AU - Tashima, Charles K.

AU - Hortobagyi, Gabriel N.

AU - Gutterman, Jordan U.

AU - Hersh, Evan M

AU - Freireich, Emil

AU - Smith, Terry L.

AU - Gehan, Edmund A.

AU - Campos, Luis T.

AU - Wheeler, Warren L.

PY - 1979/10/5

Y1 - 1979/10/5

N2 - Two hundred twenty-two patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease. (JAMA 242:1509-1513, 1979).

AB - Two hundred twenty-two patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease. (JAMA 242:1509-1513, 1979).

UR - http://www.scopus.com/inward/record.url?scp=84944965619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944965619&partnerID=8YFLogxK

U2 - 10.1001/jama.1979.03300140025017

DO - 10.1001/jama.1979.03300140025017

M3 - Article

C2 - 470088

AN - SCOPUS:84944965619

VL - 242

SP - 1509

EP - 1513

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 14

ER -